MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Other Current Assets
Current assets not reported separately, such as prepaid expenses.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets remains negative
Q1 FY2026 other current assets was $17.12M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +64.9% a year.
Context
- Other current assets amounted to 4.1% of total assets at the end of Q1 FY2026, up 4.1 pp from a year earlier.
- Other current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 19.57M USD
- Year-over-year change
- —
- 3-year CAGR
- +64.9%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.57M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 4.37M | — |
Other Current Assets vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 other current assets of $17.12M is the 4th highest of the 11 companies compared; the peer median is $5.86M.
- Other current assets amounts to 4.1% of total assets for MPLT, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.47B | +1490234.9% | -41.9% | 4.7% | |
| Mar 2026 | $109.97M | +2819.9% | +84.7% | 39.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $20.8M | — | +976.7% | 5.3% |
| Mar 2026 | $17.12M | — | +64.9% | 4.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $7.86M | +40.6% | — | 1.6% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $6.36M | +15.4% | +443.0% | 4.1% |
| Mar 2026 | $5.36M | +23221.7% | — | 1.9% | |
| Mar 2026 | $4.91M | +47.8% | — | 1.8% | |
| Mar 2026 | $4.62M | — | +27406.7% | 2.0% | |
| Dec 2025 | $396K | -44.3% | +1283.5% | 0.3% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding MPLT) | $5.86M | +44.2% | +709.9% | 2.0% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.